Clinical Trial Update: Treatment of Patients With Progressive mCRPC With 177Lu-PSMA-617 [Phase 2]

View source ↗

Summary

This is a Phase 2 trial evaluating 177Lu-PSMA-617 for progressive metastatic castration-resistant prostate cancer. The study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer with Bone Metastases

Drugs mentioned

• 177Lu-PSMA-617 (Lutetium-177 PSMA-617)

Snippet

Sponsor: Ebrahim S Delpassand | Conditions: Metastatic Castration-Resistant Prostate Cancer, Prostate Cancer Patients With Bone Metastasis | Phase 2 | Status: RECRUITING